Novo Nordisk’s weight loss pill approved by FDA

The clearance kicks off the next phase of an escalating battle for control of the obesity drug market.

The clearance kicks off the next phase of an escalating battle for control of the obesity drug market.

Two proposed rules released Monday would pare back government guardrails around health information technology software, including some put forward by the Biden administration.

On Friday, the healthcare behemoth released results of three highly anticipated external reviews that drilled down on a number of areas for improvement.

The proposed rule aims to tamp down on unwieldy price data files and change how some prices are reported.
The request for information comes as the Trump administration has largely taken a deregulatory stance on AI, in a bid to avoid hampering the technology’s rollout.

President Trump said the agreements would significantly lower the prices of prescription medicines.

The providers said they can best serve their communities by operating independently. The deal would have created a health system with more than $6 billion in annual revenue.

The value-based care pilot will be replaced by ACO LEAD, a new model that providers and analysts say seems to address many of the problems posed by its predecessor.

Under new proposed rules, hospitals would lose federal funding if they offer treatments including puberty blockers, hormone therapy or surgical procedures to minors.

PBMs are pivoting reimbursement models to protect pharmacies from what they say is an unsustainable status quo.